<DOC>
	<DOCNO>NCT01467778</DOCNO>
	<brief_summary>This Phase I study assess safety three formulation dermal implant ELAPR .</brief_summary>
	<brief_title>Safety Study Three Formulations Dermal Implant ELAPR</brief_title>
	<detailed_description>A Phase I study assess safety three formulation dermal implant ELAPR healthy subject .</detailed_description>
	<mesh_term>Skin Diseases</mesh_term>
	<criteria>Good general health status Clinically significant abnormality haematology biochemistry test Bleeding diathesis , anticoagulant drug , thrombocytopenia clinically significant prolonged APTT PT Chronic use aspirin , nonsteroidal antiinflammatory drug antiplatelet agent History keloid formation Systemic corticosteroid within last 12 week Diabetes metabolic disorder Any serious medical condition opinion investigator would strong possibility require systemic corticosteroid medication Pregnancy/lactation A history anaphylaxis allergic reaction include know hypersensitivity Hyaluronic acid lidocaine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>skin</keyword>
</DOC>